Literature DB >> 11173586

The Effect Of Long Term and High Dose Interferon Treatment In Chronic Hepatitis C.

Gábor Horváth1, Gyula Stotz, Gyula Tolvaj, Henrik Osztrogonácz, Károly Dávid.   

Abstract

The results of 43 interferon treatments of 35 patients (23 male, 12 female) are reported. The duration of the treatment was 6-18 months, the dose of interferon was 3x3-5 MU weekly. Complete response (HCV RNA became negative) was found in 11, relapse was observed in 3 patients. Partial response (transaminase levels became normal, or less than twice normal value, but patients remained HCV RNA positive) occurred in 23 cases, relapse was obeserved in 16. The therapy had no effect in 9 cases. The higher dose and longer term interferon therapy resulted in a higher rate of response to the treatment and a reduction in the number of relapses.

Entities:  

Year:  1996        PMID: 11173586     DOI: 10.1007/bf02893951

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  28 in total

Review 1.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

2.  Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia.

Authors:  J Camps; A Castilla; J Ruiz; M P Civeira; J Prieto
Journal:  J Hepatol       Date:  1993-03       Impact factor: 25.083

3.  Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Benelux Multicentre Trial Study Group.

Authors: 
Journal:  Gut       Date:  1993       Impact factor: 23.059

4.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

Review 5.  [Advances in the research on non-A, non-B hepatitis: hepatitis C virus. Multicenter anti-HCV studies].

Authors:  A Pár
Journal:  Orv Hetil       Date:  1990-10-21       Impact factor: 0.540

Review 6.  [The hepatitis C virus--principal causative agent in non-A, non-B hepatitis].

Authors:  Z Schaff; K Lapis
Journal:  Orv Hetil       Date:  1990-09-02       Impact factor: 0.540

Review 7.  Histopathology of hepatitis C virus infection.

Authors:  Z D Goodman; K G Ishak
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

8.  Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level.

Authors:  G Yamada; M Takatani; F Kishi; M Takahashi; T Doi; T Tsuji; S Shin; M Tanno; M S Urdea; J A Kolberg
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

Review 9.  [Incidence of hepatitis B, C and D infection in chronic liver diseases].

Authors:  G Horváth; G Tolvaj; K Dávid
Journal:  Orv Hetil       Date:  1992-09-27       Impact factor: 0.540

10.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

View more
  1 in total

1.  Treatment of chronic HCV infection in special populations.

Authors:  John Hoefs; Vikramjit S Aulakh
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.